Pedro Cahn

Summary

Country: Argentina

Publications

  1. ncbi Efficacy and tolerability of 10-day monotherapy with apricitabine in antiretroviral-naive, HIV-infected patients
    Pedro Cahn
    Fundacion Huesped, Angel Peluffo 3932, Buenos Aires, Argentina C120 2ABB
    AIDS 20:1261-8. 2006
  2. ncbi Multiple-dose pharmacokinetics of apricitabine, a novel nucleoside reverse transcriptase inhibitor, in patients with HIV-1 infection
    Pedro Cahn
    Fundacion Huesped, Buenos Aires, Argentina
    Clin Drug Investig 28:129-38. 2008
  3. doi Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study
    Pedro Cahn
    Fundacion Huesped, Buenos Aires, Argentina
    Lancet 382:700-8. 2013
  4. pmc Rates and reasons for early change of first HAART in HIV-1-infected patients in 7 sites throughout the Caribbean and Latin America
    Carina Cesar
    Fundacion Huesped, Buenos Aires, Argentina
    PLoS ONE 5:e10490. 2010
  5. doi Week 48 analysis of once-daily vs. twice-daily darunavir/ritonavir in treatment-experienced HIV-1-infected patients
    Pedro Cahn
    Fundacion Huesped, Buenos Aires, Argentina
    AIDS 25:929-39. 2011
  6. pmc Incidence of virological failure and major regimen change of initial combination antiretroviral therapy in the Latin America and the Caribbean: an observational cohort study
    Carina Cesar
    Fundacion Huesped, Buenos Aires, Argentina Electronic address
    Lancet HIV 2:e492-500. 2015
  7. ncbi Safe treatment interruptions in patients with nadir CD4 counts of more than 350 cells/microL: a randomized trial
    Alejandro J Krolewiecki
    Fundacion Huesped, Arca de Investigaciones Clínicas, Buenos Aires, Argentina
    J Acquir Immune Defic Syndr 41:425-9. 2006
  8. pmc Pilot, randomized study assessing safety, tolerability and efficacy of simplified LPV/r maintenance therapy in HIV patients on the 1 PI-based regimen
    Pedro Cahn
    Fundacion Huesped, Buenos Aires, Argentina
    PLoS ONE 6:e23726. 2011
  9. ncbi Predictors of adherence and virologic outcome in HIV-infected patients treated with abacavir- or indinavir-based triple combination HAART also containing lamivudine/zidovudine
    Pedro Cahn
    Fundacion Huesped, Buenos Aires, Argentina
    Curr Med Res Opin 20:1115-23. 2004
  10. ncbi Ritonavir-boosted tipranavir demonstrates superior efficacy to ritonavir-boosted protease inhibitors in treatment-experienced HIV-infected patients: 24-week results of the RESIST-2 trial
    Pedro Cahn
    Fundacion Huesped, Buenos Aires, Argentina
    Clin Infect Dis 43:1347-56. 2006

Detail Information

Publications61

  1. ncbi Efficacy and tolerability of 10-day monotherapy with apricitabine in antiretroviral-naive, HIV-infected patients
    Pedro Cahn
    Fundacion Huesped, Angel Peluffo 3932, Buenos Aires, Argentina C120 2ABB
    AIDS 20:1261-8. 2006
    ..This study evaluated the antiretroviral efficacy, tolerability and safety of apricitabine monotherapy, administered for 10 days in antiretroviral-naive, HIV-1 infected adults...
  2. ncbi Multiple-dose pharmacokinetics of apricitabine, a novel nucleoside reverse transcriptase inhibitor, in patients with HIV-1 infection
    Pedro Cahn
    Fundacion Huesped, Buenos Aires, Argentina
    Clin Drug Investig 28:129-38. 2008
    ..This study aimed to investigate the multiple-dose pharmacokinetics of apricitabine, a novel deoxycytidine analogue reverse transcriptase inhibitor, in antiretroviral-naive patients with HIV-1 infection...
  3. doi Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study
    Pedro Cahn
    Fundacion Huesped, Buenos Aires, Argentina
    Lancet 382:700-8. 2013
    ..We evaluated safety, efficacy, and emergent resistance in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV-1 with at least two-class drug resistance...
  4. pmc Rates and reasons for early change of first HAART in HIV-1-infected patients in 7 sites throughout the Caribbean and Latin America
    Carina Cesar
    Fundacion Huesped, Buenos Aires, Argentina
    PLoS ONE 5:e10490. 2010
    ..No multi-cohort study has examined rates of and reasons for change of initial HAART in this region...
  5. doi Week 48 analysis of once-daily vs. twice-daily darunavir/ritonavir in treatment-experienced HIV-1-infected patients
    Pedro Cahn
    Fundacion Huesped, Buenos Aires, Argentina
    AIDS 25:929-39. 2011
    ..twice-daily darunavir/ritonavir (DRV/r) in treatment-experienced patients with no DRV resistance-associated mutations (RAMs) at screening...
  6. pmc Incidence of virological failure and major regimen change of initial combination antiretroviral therapy in the Latin America and the Caribbean: an observational cohort study
    Carina Cesar
    Fundacion Huesped, Buenos Aires, Argentina Electronic address
    Lancet HIV 2:e492-500. 2015
    ..We assessed the incidence of and factors associated with regimen failure and regimen change of initial ART in this region...
  7. ncbi Safe treatment interruptions in patients with nadir CD4 counts of more than 350 cells/microL: a randomized trial
    Alejandro J Krolewiecki
    Fundacion Huesped, Arca de Investigaciones Clínicas, Buenos Aires, Argentina
    J Acquir Immune Defic Syndr 41:425-9. 2006
    ..To evaluate clinical, immunologic, and virologic performance of patients with nadir CD4 counts of >350 cells/microL upon treatment interruption...
  8. pmc Pilot, randomized study assessing safety, tolerability and efficacy of simplified LPV/r maintenance therapy in HIV patients on the 1 PI-based regimen
    Pedro Cahn
    Fundacion Huesped, Buenos Aires, Argentina
    PLoS ONE 6:e23726. 2011
    ....
  9. ncbi Predictors of adherence and virologic outcome in HIV-infected patients treated with abacavir- or indinavir-based triple combination HAART also containing lamivudine/zidovudine
    Pedro Cahn
    Fundacion Huesped, Buenos Aires, Argentina
    Curr Med Res Opin 20:1115-23. 2004
    ....
  10. ncbi Ritonavir-boosted tipranavir demonstrates superior efficacy to ritonavir-boosted protease inhibitors in treatment-experienced HIV-infected patients: 24-week results of the RESIST-2 trial
    Pedro Cahn
    Fundacion Huesped, Buenos Aires, Argentina
    Clin Infect Dis 43:1347-56. 2006
    ....
  11. doi Resistance profile of the new nucleoside reverse transcriptase inhibitor apricitabine
    Pedro Cahn
    Fundacion Huesped, Angel Peluffo 3932, Buenos Aires C1202ABB, Argentina
    J Antimicrob Chemother 65:213-7. 2010
    ....
  12. pmc Health outcomes among HIV-positive Latinos initiating antiretroviral therapy in North America versus Central and South America
    Carina Cesar
    Investigaciones Clínicas, Fundacion Huesped, Buenos Aires, Argentina
    J Int AIDS Soc 19:20684. 2016
    ..In this analysis, we compare HIV treatment outcomes between Latinos receiving ART in North America versus Latin America...
  13. doi Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in antiretroviral-therapy-naive adults with HIV-1 infection: 48 week results of the randomise
    Pedro Cahn
    Clinical Research Department, Fundacion Huesped, Buenos Aires, Argentina Electronic address
    Lancet Infect Dis 14:572-80. 2014
    ..We investigated whether dual therapy with lopinavir and ritonavir plus lamivudine is non-inferior to standard triple therapy...
  14. ncbi Emtricitabine: a new nucleoside analogue for once-daily antiretroviral therapy
    Pedro Cahn
    Fundacion Huesped, Angel Peluffo 3932, Buenos Aires, Argentina C1202ABB
    Expert Opin Investig Drugs 13:55-68. 2004
    ..Potency, tolerability, convenient dosing and a low rate of side effects are some of the main characteristics of this new drug...
  15. doi Clinical challenges in HIV/AIDS: Hints for advancing prevention and patient management strategies
    Omar Sued
    Fundacion Huesped, Clinical Research Department, Buenos Aires, Argentina Electronic address
    Adv Drug Deliv Rev 103:5-19. 2016
    ..In this article, we review the status of the epidemic, the latest advances in prevention and treatment, the concept of treatment as prevention and the challenges and opportunities for the HIV cure agenda. ..
  16. pmc Use of third line antiretroviral therapy in Latin America
    Carina Cesar
    Fundacion Huesped, Buenos Aires, Argentina
    PLoS ONE 9:e106887. 2014
    ..Many patients require second and third line therapy due to toxicity, tolerability, failure, or a combination of factors. The need for third line HAART, essential for program planning, is not known...
  17. doi [Lopinavir/ritonavir in new initial antiretroviral treatment strategies]
    Maria José Rolon
    Fundacion Huesped, Buenos Aires, Argentina
    Enferm Infecc Microbiol Clin 32:7-11. 2014
    ..The present review will discuss only LPV/r-based innovative strategies in initial ART regimens. ..
  18. pmc Switching to nevirapine-based regimens after undetectable viral load is not associated with increased risk of discontinuation due to toxicity
    Patricia Patterson
    Clinical Research, Fundacion Huesped, Buenos Aires, Argentina
    J Int AIDS Soc 17:19794. 2014
    ..The aim of this study is to determine the prevalence and risk factors associated with development of toxicity or treatment discontinuation in patients switching to NVP-based regimens...
  19. ncbi Raltegravir: a new antiretroviral class for salvage therapy
    Pedro Cahn
    Department of Clinical Research, Fundacion Huesped, Buenos Aires, Argentina C1202ABB
    Lancet 369:1235-6. 2007
  20. ncbi Tuberculosis and HIV: a partnership against the most vulnerable
    Pedro Cahn
    Fundacion Huesped, Angel Peluffo 3932 C1202ABB, Buenos Aires, Argentina
    J Int Assoc Physicians AIDS Care (Chic) 2:106-23. 2003
    ..Global distributive injustices in wealth, the burden of disease, and the provision of healthcare are obvious in TB, and clearly show us that the needs of the most vulnerable populations must be met in order to address the problems...
  21. ncbi Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial
    José Valdez Madruga
    Centro de Referência e Treinamento DST AIDS, Sao Paulo, Brazil
    Lancet 370:29-38. 2007
    ..The aim of this trial was to assess the efficacy, safety, and tolerability of TMC125 (etravirine), a non-nucleoside reverse transcriptase inhibitor (NNRTI)...
  22. ncbi The intestinal mucosa as a reservoir of HIV-1 infection after successful HAART
    Liliana Belmonte
    Instituto de Investigaciones Hematologicas, Academia Nacional de Medicina, Buenos Aires, Argentina
    AIDS 21:2106-8. 2007
    ..The intestinal mucosa seems to serve as a reservoir poorly influenced by levels of plasma viral load or HAART...
  23. ncbi Pharmacokinetics of two randomized trials evaluating the safety and efficacy of indinavir, saquinavir and lopinavir in combination with low-dose ritonavir: the MaxCmin1 and 2 trials
    Ulrik S Justesen
    Department of Infectious Diseases, Odense University Hospital, Odense C, Denmark
    Basic Clin Pharmacol Toxicol 101:339-44. 2007
    ..Associations between high C(min) and toxicity were identified in the saquinavir arm; therefore, dose reductions may be appropriate in certain patients with C(min) several times above the minimum effective concentration...
  24. ncbi Management of human immunodeficiency virus-infected pregnant women at Latin American and Caribbean sites
    Jennifer S Read
    National Institute of Child Health and Human Development, Bethesda, Maryland, USA
    Obstet Gynecol 109:1358-67. 2007
    ....
  25. ncbi Low rate of emergence of nevirapine and lamivudine resistance after post-partum interruption of a triple-drug regimen
    Hector Perez
    Fernandes Hospital, Infectious Diseases Unit, Buenos Aires, Argentina
    Antivir Ther 13:135-9. 2008
    ..The aim of this study was to evaluate the emergence of strains resistant to NVP and lamivudine (3TC) after discontinuation of antiretroviral therapy (ART) with 3TC/zidovudine (ZDV)/NVP...
  26. pmc Determinants of treatment access in a population-based cohort of HIV-positive men and women living in Argentina
    Carlos Zala
    Fundacion Dra Cecilia Grierson, Buenos Aires, Argentina
    Medscape J Med 10:78. 2008
    ..To report emerging data on the use of highly active antiretroviral therapy (HAART) in Argentina by assessing patterns of HAART access and late vs early treatment initiation in a population-based cohort of adults infected with HIV type-1...
  27. pmc Antiretroviral resistance among HIV type 1-infected women first exposed to antiretrovirals during pregnancy: plasma versus PBMCs
    Luis E Soto-Ramirez
    Department of Infectious Diseases, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico, DF, Mexico
    AIDS Res Hum Retroviruses 24:797-804. 2008
    ..The prevalence of RAMs among these pregnant, HIV-1-infected women is high (15%). Rates of detection of RAMs in plasma and PBMC samples were similar...
  28. pmc Efficacy, safety and tolerability of tipranavir coadministered with ritonavir in HIV-1-infected children and adolescents
    Juan C Salazar
    Connecticut Children s Medical Center, University of Connecticut School of Medicine, Hartford, Connecticut 06106, USA
    AIDS 22:1789-98. 2008
    ..To evaluate the efficacy, safety and tolerability of ritonavir-boosted tipranavir (TPV/r) in HIV-1-infected pediatric patients...
  29. pmc Uncommon hepatitis B virus and/or hepatitis C virus occult infection in HIV-positive patients with abnormal level of hepatic enzyme
    Natalia Laufer
    J Acquir Immune Defic Syndr 49:233-4. 2008
  30. ncbi Continued indinavir versus switching to indinavir/ritonavir in HIV-infected patients with suppressed viral load
    Juan A Arnaiz
    Hospital Clinic IDIBAPS, University of Barcelona, Spain
    AIDS 17:831-40. 2003
    ....
  31. doi Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel
    Scott M Hammer
    Division of Infectious Diseases, Columbia University College of Physicians and Surgeons, 630 W 168th St, New York, NY 10032, USA
    JAMA 300:555-70. 2008
    ....
  32. ncbi Abacavir once or twice daily combined with once-daily lamivudine and efavirenz for the treatment of antiretroviral-naive HIV-infected adults: results of the Ziagen Once Daily in Antiretroviral Combination Study
    Graeme J Moyle
    Chelsea and Westminster Hospital, HIV Clinic, London, United Kingdom
    J Acquir Immune Defic Syndr 38:417-25. 2005
    ..7%). ABC administered once daily in combination with 3TC and EFV administered once daily was non-inferior to the ABC twice-daily dosing schedule when combined with 3TC and EFV over 48 weeks...
  33. pmc Origin of human immunodeficiency virus type 1 quasispecies emerging after antiretroviral treatment interruption in patients with therapeutic failure
    Gustavo H Kijak
    National Reference Center for AIDS, Department of Microbiology, School of Medicine, University of Buenos Aires, Argentina
    J Virol 76:7000-9. 2002
    ..This study demonstrates the important role that the reemergence of quasispecies plays in HIV-1 population dynamics and points out the difficulties that may be found when recycling ARV therapies with patients with treatment failure...
  34. ncbi A randomized clinical trial comparing nelfinavir or nevirapine associated to zidovudine/lamivudine in HIV-infected naive patients (the Combine Study)
    Daniel Podzamczer
    Infectious Disease Service, Ciutat Sanitaria de Bellvitge, L Hospitalet, Barcelona, Spain
    Antivir Ther 7:81-90. 2002
    ....
  35. ncbi Forty-eight-week evaluation of lopinavir/ritonavir, a new protease inhibitor, in human immunodeficiency virus-infected children
    Xavier Saez-Llorens
    Hospital del Nino, Panama City, Panama
    Pediatr Infect Dis J 22:216-24. 2003
    ..Lopinavir/ritonavir has demonstrated antiviral activity in the HIV-infected adult...
  36. ncbi Randomized, controlled study of the effects of a short course of prednisone on the incidence of rash associated with nevirapine in patients infected with HIV-1
    Julio S G Montaner
    St Paul s Hospital University of British Columbia, Vancouver, British Columbia, Canada
    J Acquir Immune Defic Syndr 33:41-6. 2003
    ..To examine the effect of 2 weeks of treatment with prednisone on the incidence of nevirapine-associated rash in HIV-1-infected patients receiving combination antiretroviral therapy...
  37. ncbi Dose-ranging, randomized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naive subjects: 48-week results
    Robert L Murphy
    Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA
    AIDS 17:2603-14. 2003
    ..To compare the efficiency and safety of atazanavir and nelfinavir in antiretroviral-naive patients...
  38. ncbi Efficacy and safety of emtricitabine vs stavudine in combination therapy in antiretroviral-naive patients: a randomized trial
    Michael S Saag
    University of Alabama Research Clinic, Birmingham, USA
    JAMA 292:180-9. 2004
    ..Emtricitabine is a new, once-daily nucleoside reverse transcriptase inhibitor (NRTI) with potent activity against human immunodeficiency virus (HIV)...
  39. ncbi Triple nucleoside treatment with abacavir plus the lamivudine/zidovudine combination tablet (COM) compared to indinavir/COM in antiretroviral therapy-naïve adults: results of a 48-week open-label, equivalence trial (CNA3014)
    Asda Vibhagool
    Medicine Department, Faculty of Medicine, Ramathibodi Hospital Mahidol University, Bangkok, Thailand
    Curr Med Res Opin 20:1103-14. 2004
    ..a regimen containing the protease inhibitor indinavir (IDV) 800 mg three times daily plus COM twice daily (IDV/COM) in antiretroviral-naïve, HIV-infected patients...
  40. ncbi Higher rate of toxicity with no increased efficacy when hydroxyurea is added to a regimen of stavudine plus didanosine and nevirapine in primary HIV infection
    Carlos Zala
    Fundación Huesped and Department of Microbiology, School of Medicine, University of Buenos Aires, Argentina
    J Acquir Immune Defic Syndr 29:368-73. 2002
    ..05). Our results suggest that that adding hydroxyurea to a regimen of d4T plus ddI and NVP increases toxicity without improving the antiviral effect...
  41. ncbi Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSista
    Charles B Hicks
    Division of Infectious Diseases and International Health, Duke University Medical Center, Durham, NC 27710, USA
    Lancet 368:466-75. 2006
    ....
  42. ncbi Cohort Profile: Caribbean, Central and South America Network for HIV research (CCASAnet) collaboration within the International Epidemiologic Databases to Evaluate AIDS (IeDEA) programme
    Catherine C McGowan
    Vanderbilt University School of Medicine, Nashville, TN, USA
    Int J Epidemiol 36:969-76. 2007
  43. ncbi Randomized trial to evaluate indinavir/ritonavir versus saquinavir/ritonavir in human immunodeficiency virus type 1-infected patients: the MaxCmin1 Trial
    Ulrik Bak Dragsted
    Hvidovre University Hospital, Hvidovre, Denmark
    J Infect Dis 188:635-42. 2003
    ..A greater number of treatment-limiting adverse events were observed in the Idv/Rtv arm, relative to the Sqv/Rtv arm. In conclusion, Rtv-boosed Sqv and Idv were found to have comparable antiretroviral effects in the doses studied...
  44. ncbi [Current treatment of HIV infection ]
    Pedro Cahn
    Servicio de Infectologia, Hospital JA Fernández, GCBA
    Acta Gastroenterol Latinoam 36:S41-3; discussion S74-82. 2006
  45. ncbi The Sydney Declaration: a call to scale up research
    David Cooper
    University of New South Wales, Sydney, NSW, Australia
    Lancet 370:7-8. 2007
  46. ncbi Venous and arterial blood lactate in HIV-infected patients
    Carlos Zala
    Antivir Ther 7:309-10. 2002
  47. ncbi Time to act: global apathy towards HIV/AIDS is a crime against humanity
    Robert Hogg
    Department of Health Care and Epidemiology and BC Center for Excellence in HIV AIDS, University of British Columbia
    Lancet 360:1710-1. 2002
  48. ncbi Apricitabine: a novel deoxycytidine analogue nucleoside reverse transcriptase inhibitor for the treatment of nucleoside-resistant HIV infection
    Mark A Wainberg
    McGill University AIDS Center, Lady Davis Institute Jewish General Hospital, Montreal, Canada
    Antivir Chem Chemother 18:61-70. 2007
    ..Further studies to evaluate the long-term efficacy and tolerability of ATC are underway...
  49. ncbi AIDS and globalization: the Argentinean crisis
    Pedro Cahn
    AIDS 16:10-11. 2002
  50. ncbi Discontinuation of maintenance therapy for cryptococcal meningitis in patients with AIDS treated with highly active antiretroviral therapy: an international observational study
    Cristina Mussini
    Clinic of Infectious and Tropical Diseases, University of Modena and Reggio Emilia, Azienda Policlinico, Modena, Italy
    Clin Infect Dis 38:565-71. 2004
    ..Recurrent cryptococcal infection should be suspected in patients whose serum cryptococcal antigen test results revert back to positive after discontinuation of maintenance therapy...
  51. ncbi Cytomegalovirus UL97 mutations associated with ganciclovir resistance in immunocompromised patients from Argentina
    Silvia Sánchez Puch
    Clinical Virology Laboratory, CEMIC University Hospital, Galvan 4102, C1431FWN Buenos Aires, Argentina
    J Clin Virol 30:271-5. 2004
    ..Prolonged therapy with ganciclovir (GCV) can result in the development of GCV-resistant strains due to mutations in the viral phosphotransferase (UL97 gene) and/or in the viral DNA polymerase (UL54 gene)...
  52. ncbi [Endoscopic approach in HIV infected-patients with upper gastrointestinal symptoms]
    Martín Alejandro Olmos
    División de Gastroenterología, Hospital Fernandez, Buenos Aires, Argentina
    Acta Gastroenterol Latinoam 34:120-6. 2004
    ....
  53. doi Laboratory abnormalities among HIV-1-infected pregnant women receiving antiretrovirals in Latin America and the Caribbean
    Mariana Ceriotto
    Hospital Cecilia Grierson, Buenos Aires, Argentina
    AIDS Patient Care STDS 22:167-71. 2008
  54. ncbi Comparable pharmacokinetics of generic indinavir (Inhibisam) versus brand indinavir (Crixivan) when boosted with ritonavir
    Carlos Zala
    J Acquir Immune Defic Syndr 38:363-4. 2005
  55. ncbi Coinfection: Helicobacter pylori/human immunodeficiency virus
    Martin Olmos
    Hospital Fernandez, Buenos Aires, Argentina
    Dig Dis Sci 49:1836-9. 2004
    ..HIV-infected patients with H. pylori had a higher mean CD4 count than HIV-infected individuals without H. pylori. Gastric lesions associated with H. pylori were more severe in the HIV-positive population...
  56. pmc Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1
    Frank van Leth
    International Antiviral Therapy Evaluation Center, Division of Infectious Diseases, Tropical Medicine, and AIDS, Department of Internal Medicine, Academic Medical Center, University of Amsterdam, The Netherlands
    PLoS Med 1:e19. 2004
    ..We analysed whether lipid changes differed between the two most commonly used NNRTIs, nevirapine (NVP) and efavirenz (EFV)...
  57. pmc Determination of the underlying cause of death in three multicenter international HIV clinical trials
    Alan R Lifson
    University of Minnesota, Minneapolis, Minnesota 55454 1015, USA
    HIV Clin Trials 9:177-85. 2008
    ..Describe processes and challenges for an Endpoint Review Committee (ERC) in determining and adjudicating underlying causes of death in HIV clinical trials...
  58. pmc Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration
    Rami Kantor
    Division of Infectious Disease and Center for AIDS Research, Stanford University, Stanford, California, USA
    PLoS Med 2:e112. 2005
    ..The genetic differences among HIV-1 subtypes may be critical to clinical management and drug resistance surveillance as antiretroviral treatment is expanded to regions of the world where diverse non-subtype-B viruses predominate...
  59. pmc Discordances between interpretation algorithms for genotypic resistance to protease and reverse transcriptase inhibitors of human immunodeficiency virus are subtype dependent
    Joke Snoeck
    Rega Institute for Medical Research, Minderbroedersstraat 10, 3000 Leuven, Belgium
    Antimicrob Agents Chemother 50:694-701. 2006
    ..It is not yet known whether therapy response is subtype dependent, but the advice given to clinicians based on a genotypic interpretation algorithm differs according to the subtype...
  60. ncbi Long-term efficacy and safety of atazanavir with stavudine and lamivudine in patients previously treated with nelfinavir or atazanavir
    Robin Wood
    Somerset Hospital, Capetown, South Africa and Chulalongkorn University, Bangkok, Thailand
    J Acquir Immune Defic Syndr 36:684-92. 2004
    ..In virologically suppressed nelfinavir-treated patients switched to atazanavir, virologic improvement continued, whereas nelfinavir-induced lipid elevations were reversed within 12 weeks, approaching pretreatment values...
  61. pmc Magnitude, breadth, and functional profile of T-cell responses during human immunodeficiency virus primary infection with B and BF viral variants
    Gabriela Turk
    Centro Nacional de Referencia para el SIDA, Facultad de Medicina, Universidad de Buenos Aires, Paraguay 2155 Piso 11, C1121ABG Buenos Aires, Argentina
    J Virol 82:2853-66. 2008
    ..Screening T-cell responses with multiple sets increased sensitivity. Further support for the notion of polyfunctional CD8(+) T-cell requirement to better control viral replication is also provided...